Covered recipient · General Payments record
CHAITALI SINGH NANGIA
Allopathic & Osteopathic Physicians Internal Medicine Hematology & Oncology
A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.
Saved only in this browser. No account or alerts.
General Payments · PY2022 · Entire year
$86,950.83
161 records · 0 disputed
“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”
— Centers for Medicare & Medicaid Services, Open Payments
A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.
These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.
A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.
How these totals are calculated
- This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
- General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
- Methodology & Data — sourcing, labeling, and limitations.
Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗
By nature of payment
PY2022 · entire year · sorted by reported total
| Nature of payment | Amount | Records |
|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $40,215.82 | 14 |
| Consulting Fee | $38,681.50 | 18 |
| Travel and Lodging | $4,888.59 | 14 |
| Food and Beverage | $3,164.92 | 115 |
By paying entity
PY2022 · entire year · sorted by reported total
Page 3 of 4; records 101–150 of 161 matching records. This page contains 50 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.
IndustryPayments · General Payments
CHAITALI SINGH NANGIA
NPI 1669425286 · CMS profile ID 894263
Allopathic & Osteopathic Physicians / Internal Medicine / Hematology & Oncology
COSTA MESA, CA
A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.
A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.
General Payments, PY2022; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types
Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00
Page 3 of 4; records 101–150 of 161 matching records. This page contains 50 records (maximum 50), not the full filtered export.
Filtered page: https://industrypayments.org/provider/npi-1669425286?year=2022&recipient=provider&page=3#records-h
CMS source: https://openpaymentsdata.cms.gov/dataset/df01c2f8-dc1f-4e79-96cb-8208beaf143c
Cite these filtered records
The citation includes this program year, filters, data edition, and page of results.
- Plain
- CHAITALI SINGH NANGIA, NPI 1669425286, CMS profile ID 894263. General Payments, PY2022; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 3 of 4; records 101–150 of 161 matching records. This page contains 50 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1669425286?year=2022&recipient=provider&page=3#records-h. Source: https://openpaymentsdata.cms.gov/dataset/df01c2f8-dc1f-4e79-96cb-8208beaf143c.
- APA 7
- IndustryPayments. (2026). CHAITALI SINGH NANGIA, NPI 1669425286, CMS profile ID 894263. General Payments, PY2022; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 3 of 4; records 101–150 of 161 matching records. This page contains 50 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1669425286?year=2022&recipient=provider&page=3#records-h. Source: https://openpaymentsdata.cms.gov/dataset/df01c2f8-dc1f-4e79-96cb-8208beaf143c.
- Bluebook
- CHAITALI SINGH NANGIA, NPI 1669425286, CMS profile ID 894263, IndustryPayments, General Payments, PY2022; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 3 of 4; records 101–150 of 161 matching records. This page contains 50 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/df01c2f8-dc1f-4e79-96cb-8208beaf143c. https://industrypayments.org/provider/npi-1669425286?year=2022&recipient=provider&page=3#records-h.
Centers for Medicare & Medicaid Services, Open Payments
Citation formats are provided for reference; check the requirements of your publication.
Payment records · PY2022
Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them
General Payments · PY2022 · Physicians and non-physician practitioners · CMS publication 2026-06-30
161 matching records · $86,950.83 reported total · 0 disputed
Nature of payment: All payment types
Records imported here (UTC).
CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.
Showing records 101–150 of 161.
| Paying entity | Amount | Date | Nature of payment | Dispute status | Publication flags | Published | Record ID | Source |
|---|---|---|---|---|---|---|---|---|
| SERVIER PHARMACEUTICALS LLC | $22.15 | 05/27/2022 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 964202621 | CMS |
| GENZYME CORPORATION | $2,552.00 | 05/26/2022 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 938935865 | CMS |
| Regeneron Healthcare Solutions, Inc. | $1,458.00 | 05/26/2022 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 927297781 | CMS |
| Regeneron Healthcare Solutions, Inc. | $7,655.00 | 05/26/2022 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 927297785 | CMS |
| Regeneron Healthcare Solutions, Inc. | $240.00 | 05/25/2022 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 927297776 | CMS |
| Regeneron Healthcare Solutions, Inc. | $240.00 | 05/24/2022 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 927297771 | CMS |
| TerSera Therapeutics LLC | $33.58 | 05/24/2022 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 943238355 | CMS |
| Regeneron Healthcare Solutions, Inc. | $299.63 | 05/20/2022 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 927297761 | CMS |
| Regeneron Healthcare Solutions, Inc. | $121.88 | 05/20/2022 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 927297765 | CMS |
| GENZYME CORPORATION | $97.32 | 05/19/2022 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 938935869 | CMS |
| GENZYME CORPORATION | $7,655.00 | 05/19/2022 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 938936001 | CMS |
| GENZYME CORPORATION | $411.13 | 05/19/2022 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 938936003 | CMS |
| GENZYME CORPORATION | $984.50 | 05/19/2022 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 938936005 | CMS |
| EISAI INC. | $16.13 | 05/17/2022 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 908025137 | CMS |
| E.R. Squibb & Sons, L.L.C. | $22.35 | 05/16/2022 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 932812255 | CMS |
| Bayer HealthCare Pharmaceuticals Inc. | $19.16 | 05/13/2022 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 930622849 | CMS |
| Regeneron Healthcare Solutions, Inc. | $21.00 | 05/11/2022 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 927297751 | CMS |
| Regeneron Healthcare Solutions, Inc. | $335.53 | 05/11/2022 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 927297755 | CMS |
| GENZYME CORPORATION | $969.57 | 05/10/2022 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 938936095 | CMS |
| Merck Sharp & Dohme LLC | $20.13 | 05/10/2022 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 944164997 | CMS |
| Janssen Biotech, Inc. | $27.72 | 05/09/2022 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 885532355 | CMS |
| Seagen Inc. | $22.92 | 05/06/2022 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 904127263 | CMS |
| Amgen Inc. | $24.32 | 05/02/2022 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 939219405 | CMS |
| Gilead Sciences, Inc. | $3,170.00 | 05/02/2022 | Consulting Fee | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 929448189 | CMS |
| Incyte Corporation | $18.81 | 04/23/2022 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 943018165 | CMS |
| Seagen Inc. | $20.20 | 04/18/2022 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 904127277 | CMS |
| Gilead Sciences, Inc. | $22.57 | 04/16/2022 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 929573217 | CMS |
| Lilly USA, LLC | $5,000.00 | 04/15/2022 | Consulting Fee | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 917941581 | CMS |
| Coherus Biosciences Inc. | $18.10 | 04/12/2022 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 956566679 | CMS |
| Coherus Biosciences Inc. | $2.61 | 04/12/2022 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 956566681 | CMS |
| Gilead Sciences, Inc. | $23.09 | 04/10/2022 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 929573219 | CMS |
| Taiho Oncology, Inc. | $19.71 | 04/05/2022 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 924013293 | CMS |
| PUMA BIOTECHNOLOGY, INC. | $27.45 | 04/01/2022 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 942302259 | CMS |
| E.R. Squibb & Sons, L.L.C. | $21.46 | 03/29/2022 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 932812235 | CMS |
| AstraZeneca Pharmaceuticals LP | $22.89 | 03/28/2022 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 915598023 | CMS |
| AstraZeneca Pharmaceuticals LP | $17.07 | 03/22/2022 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 915734415 | CMS |
| Lilly USA, LLC | $21.36 | 03/18/2022 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 917938303 | CMS |
| Regeneron Healthcare Solutions, Inc. | $1,458.00 | 03/15/2022 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 927297747 | CMS |
| ARRAY BIOPHARMA INC | $16.29 | 03/14/2022 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 949074769 | CMS |
| Deciphera Pharmaceuticals Inc. | $22.60 | 03/11/2022 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 953435067 | CMS |
| EISAI INC. | $15.01 | 03/08/2022 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 908025145 | CMS |
| Boehringer Ingelheim Pharmaceuticals, Inc. | $18.01 | 03/07/2022 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 887420509 | CMS |
| Regeneron Healthcare Solutions, Inc. | $1,823.00 | 03/03/2022 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 927297741 | CMS |
| E.R. Squibb & Sons, L.L.C. | $0.20 | 02/28/2022 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 932812243 | CMS |
| E.R. Squibb & Sons, L.L.C. | $19.24 | 02/28/2022 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 932812245 | CMS |
| Blueprint Medicines Corporation | $22.83 | 02/25/2022 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 958934493 | CMS |
| CSL Behring | $27.25 | 02/22/2022 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 940918749 | CMS |
| Gilead Sciences, Inc. | $3,170.00 | 02/18/2022 | Consulting Fee | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 929448197 | CMS |
| Foundation Medicine, Inc. | $19.33 | 02/11/2022 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 924045155 | CMS |
| GENZYME CORPORATION | $1,276.00 | 02/08/2022 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 938935793 | CMS |
By program year
All program years on this page · sorted by year
Source & provenance
- Dataset
- CMS Open Payments — General Payments
- Publisher of source data
- Centers for Medicare & Medicaid Services
- CMS publication date
- 2026-06-30
- Program years on this page
- 2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
- Source files
- Dataset page · Bulk file · PY2019 , PY2020 , PY2021 , PY2022 , PY2023 , PY2024 , PY2025
- Generated from
- OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv
One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.
Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.
Research Payments
One row per program year and role, newest year first · amounts for the two roles are never added together
| Program year | Role | Amount | Records |
|---|---|---|---|
| PY2025 | Principal investigator | $453,013.97 | 128 |
| PY2024 | Principal investigator | $201,017.41 | 21 |
| PY2023 | Principal investigator | $160,924.81 | 7 |
| PY2022 | Principal investigator | $168,687.91 | 6 |
| PY2021 | Principal investigator | $260,000.00 | 1 |
| PY2020 | Principal investigator | $10,946.62 | 2 |
Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.
“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”
— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224
Research Payments records · PY2025
Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them
128 records in PY2025
| Role | Paying entity | Amount | Date | Recipient | Study | Dispute status | Published | Record ID |
|---|---|---|---|---|---|---|---|---|
| Principal investigator 1 | JAZZ PHARMACEUTICALS INC. | $752.00 | 12/31/2025 | Non-covered Recipient Entity Hoag Memorial Hospital Presbyterian | I-SPY Trial (Investigation of Serial Studies to Predict Your Therapeutic Response With Imaging And moLecular Analysis 2) | No dispute reported | 06/30/2026 | 1233739999 |
| Principal investigator 1 | Merck Sharp & Dohme LLC | $35,345.48 | 12/31/2025 | Non-covered Recipient Entity Hoag Memorial Hospital Presbyterian | A Phase 3, Randomized, Open-label Study to Evaluate the Efficacy and Safety of sac-TMT Sacituzumab Tirumotecan, MK-2870 Followed by Carboplatin,Paclitaxel vs Chemotherapy, Both in Combination With Pembrolizumab as Neoadjuvant Therapy for High-Risk, Earl | No dispute reported | 06/30/2026 | 1232924402 |
| Principal investigator 1 | Merck Sharp & Dohme LLC | $17,540.72 | 12/31/2025 | Non-covered Recipient Entity Hoag Memoriall Hospital Presbyterian | A Phase III, Randomized, Open-label Study to Evaluate Pembrolizumab as Neoadjuvant Therapy and in Combination With Standard of Care as Adjuvant Therapy for Stage III-IVA Resectable Locoregionally Advanced Head and Neck Squamous Cell Carcinoma LA HNSCC | No dispute reported | 06/30/2026 | 1232926845 |
| Principal investigator 1 | PFIZER INC. | $1,382.40 | 12/31/2025 | Non-covered Recipient Entity Hoag Memorial Hospital Presbyterian | AN INTERVENTIONAL OPENLABEL RANDOMIZED MULTICENTER PHASE 3 STUDY OF PF07220060 PLUS LETROZOLE COMPARED TO CDK46 INHIBITOR PLUS LETROZOLE IN PARTICIPANTS OVER 18 YEARS OF AGE WITH HORMONE RECEPTOR HRPOSITIVE HER2NEGATIVE ADVANCEDMETASTATIC BREAST CANCER WHO HAVE NOT RECEIVED ANY PRIOR SYSTEMIC ANTICANCER TREATMENT FOR ADVANCEDMETASTATIC DISEASE FOURLIGHT3 | No dispute reported | 06/30/2026 | 1228745204 |
| Principal investigator 1 | PFIZER INC. | $2,447.56 | 12/27/2025 | Non-covered Recipient Entity Hoag Memorial Hospital Presbyterian | AN INTERVENTIONAL OPENLABEL RANDOMIZED MULTICENTER PHASE 3 STUDY OF PF07220060 PLUS LETROZOLE COMPARED TO CDK46 INHIBITOR PLUS LETROZOLE IN PARTICIPANTS OVER 18 YEARS OF AGE WITH HORMONE RECEPTOR HRPOSITIVE HER2NEGATIVE ADVANCEDMETASTATIC BREAST CANCER WHO HAVE NOT RECEIVED ANY PRIOR SYSTEMIC ANTICANCER TREATMENT FOR ADVANCEDMETASTATIC DISEASE FOURLIGHT3 | No dispute reported | 06/30/2026 | 1228733009 |
| Principal investigator 1 | PFIZER INC. | $7,419.60 | 12/13/2025 | Non-covered Recipient Entity Hoag Memorial Hospital Presbyterian | AN INTERVENTIONAL OPENLABEL RANDOMIZED MULTICENTER PHASE 3 STUDY OF PF07220060 PLUS LETROZOLE COMPARED TO CDK46 INHIBITOR PLUS LETROZOLE IN PARTICIPANTS OVER 18 YEARS OF AGE WITH HORMONE RECEPTOR HRPOSITIVE HER2NEGATIVE ADVANCEDMETASTATIC BREAST CANCER WHO HAVE NOT RECEIVED ANY PRIOR SYSTEMIC ANTICANCER TREATMENT FOR ADVANCEDMETASTATIC DISEASE FOURLIGHT3 | No dispute reported | 06/30/2026 | 1228738203 |
| Principal investigator 1 | PFIZER INC. | $22.50 | 12/04/2025 | Non-covered Recipient Entity Hoag Memorial Hospital | AN INTERVENTIONAL OPENLABEL RANDOMIZED MULTICENTER PHASE 3 STUDY OF PF07220060 PLUS LETROZOLE COMPARED TO CDK46 INHIBITOR PLUS LETROZOLE IN PARTICIPANTS OVER 18 YEARS OF AGE WITH HORMONE RECEPTOR HRPOSITIVE HER2NEGATIVE ADVANCEDMETASTATIC BREAST CANCER WHO HAVE NOT RECEIVED ANY PRIOR SYSTEMIC ANTICANCER TREATMENT FOR ADVANCEDMETASTATIC DISEASE FOURLIGHT3 | No dispute reported | 06/30/2026 | 1228716351 |
| Principal investigator 1 | PFIZER INC. | $6,050.70 | 11/26/2025 | Non-covered Recipient Entity Hoag Memorial Hospital Presbyterian | AN INTERVENTIONAL OPENLABEL RANDOMIZED MULTICENTER PHASE 3 STUDY OF PF07220060 PLUS LETROZOLE COMPARED TO CDK46 INHIBITOR PLUS LETROZOLE IN PARTICIPANTS OVER 18 YEARS OF AGE WITH HORMONE RECEPTOR HRPOSITIVE HER2NEGATIVE ADVANCEDMETASTATIC BREAST CANCER WHO HAVE NOT RECEIVED ANY PRIOR SYSTEMIC ANTICANCER TREATMENT FOR ADVANCEDMETASTATIC DISEASE FOURLIGHT3 | No dispute reported | 06/30/2026 | 1228738547 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $492.00 | 11/14/2025 | Non-covered Recipient Entity HOAG MEMORIAL HOSPITAL PRESBYTERIAN | A Phase 2 and Phase 3 Peri-operative Trial of Fianlimab and Cemiplimab Compared With Anti-PD1 Alone in Patients With Resectable Stage III and IV Melanoma | No dispute reported | 06/30/2026 | 1184261389 |
| Principal investigator 1 | PFIZER INC. | $1,981.80 | 11/04/2025 | Non-covered Recipient Entity Hoag Memorial Hospital Presbyterian | AN INTERVENTIONAL SAFETY AND EFFICACY PHASE 1B2 OPENLABEL STUDY TO INVESTIGATE TOLERABILITY PK AND ANTITUMOR ACTIVITY OF VEPDEGESTRANT ARV471PF07850327 AN ORAL PROTEOLYSIS TARGETING CHIMERA IN COMBINATION WITH PF07220060 IN PARTICIPANTS AGED 18 YEARS AND OLDER WITH ERHER2 ADVANCED OR METASTATIC BREAST CANCER | No dispute reported | 06/30/2026 | 1228728825 |
| Principal investigator 1 | PFIZER INC. | $15.00 | 11/03/2025 | Non-covered Recipient Entity Hoag Memorial Hospital | AN INTERVENTIONAL OPENLABEL RANDOMIZED MULTICENTER PHASE 3 STUDY OF PF07220060 PLUS LETROZOLE COMPARED TO CDK46 INHIBITOR PLUS LETROZOLE IN PARTICIPANTS OVER 18 YEARS OF AGE WITH HORMONE RECEPTOR HRPOSITIVE HER2NEGATIVE ADVANCEDMETASTATIC BREAST CANCER WHO HAVE NOT RECEIVED ANY PRIOR SYSTEMIC ANTICANCER TREATMENT FOR ADVANCEDMETASTATIC DISEASE FOURLIGHT3 | No dispute reported | 06/30/2026 | 1228716523 |
| Principal investigator 1 | Day One Biopharmaceuticals | $363.29 | 10/27/2025 | Non-covered Recipient Entity HOAG MEMORIAL HOSPITAL PRESBYTERIAN | Subprotocol of DAY101 in Combination with Pimasertib | No dispute reported | 06/30/2026 | 1240091731 |
| Principal investigator 1 | Day One Biopharmaceuticals | $883.31 | 10/27/2025 | Non-covered Recipient Entity HOAG MEMORIAL HOSPITAL PRESBYTERIAN | Subprotocol of DAY101 in Combination with Pimasertib | No dispute reported | 06/30/2026 | 1240091733 |
| Principal investigator 1 | Day One Biopharmaceuticals | $438.61 | 10/27/2025 | Non-covered Recipient Entity HOAG MEMORIAL HOSPITAL PRESBYTERIAN | Subprotocol of DAY101 in Combination with Pimasertib | No dispute reported | 06/30/2026 | 1240091735 |
| Principal investigator 1 | Day One Biopharmaceuticals | $438.61 | 10/27/2025 | Non-covered Recipient Entity HOAG MEMORIAL HOSPITAL PRESBYTERIAN | Subprotocol of DAY101 in Combination with Pimasertib | No dispute reported | 06/30/2026 | 1240091737 |
| Principal investigator 1 | Day One Biopharmaceuticals | $40.36 | 10/27/2025 | Non-covered Recipient Entity HOAG MEMORIAL HOSPITAL PRESBYTERIAN | Subprotocol of DAY101 in Combination with Pimasertib | No dispute reported | 06/30/2026 | 1240091739 |
| Principal investigator 1 | Day One Biopharmaceuticals | $48.74 | 10/27/2025 | Non-covered Recipient Entity HOAG MEMORIAL HOSPITAL PRESBYTERIAN | Subprotocol of DAY101 in Combination with Pimasertib | No dispute reported | 06/30/2026 | 1240091741 |
| Principal investigator 1 | Day One Biopharmaceuticals | $438.61 | 10/27/2025 | Non-covered Recipient Entity HOAG MEMORIAL HOSPITAL PRESBYTERIAN | Subprotocol of DAY101 in Combination with Pimasertib | No dispute reported | 06/30/2026 | 1240091743 |
| Principal investigator 1 | Day One Biopharmaceuticals | $363.29 | 10/27/2025 | Non-covered Recipient Entity HOAG MEMORIAL HOSPITAL PRESBYTERIAN | Subprotocol of DAY101 in Combination with Pimasertib | No dispute reported | 06/30/2026 | 1240091745 |
| Principal investigator 1 | Day One Biopharmaceuticals | $48.74 | 10/27/2025 | Non-covered Recipient Entity HOAG MEMORIAL HOSPITAL PRESBYTERIAN | Subprotocol of DAY101 in Combination with Pimasertib | No dispute reported | 06/30/2026 | 1240091747 |
| Principal investigator 1 | Day One Biopharmaceuticals | $40.36 | 10/27/2025 | Non-covered Recipient Entity HOAG MEMORIAL HOSPITAL PRESBYTERIAN | Subprotocol of DAY101 in Combination with Pimasertib | No dispute reported | 06/30/2026 | 1240091749 |
| Principal investigator 1 | Day One Biopharmaceuticals | $48.74 | 10/27/2025 | Non-covered Recipient Entity HOAG MEMORIAL HOSPITAL PRESBYTERIAN | Subprotocol of DAY101 in Combination with Pimasertib | No dispute reported | 06/30/2026 | 1240091751 |
| Principal investigator 1 | Day One Biopharmaceuticals | $438.61 | 10/27/2025 | Non-covered Recipient Entity HOAG MEMORIAL HOSPITAL PRESBYTERIAN | Subprotocol of DAY101 in Combination with Pimasertib | No dispute reported | 06/30/2026 | 1240091753 |
| Principal investigator 1 | Day One Biopharmaceuticals | $48.74 | 10/27/2025 | Non-covered Recipient Entity HOAG MEMORIAL HOSPITAL PRESBYTERIAN | Subprotocol of DAY101 in Combination with Pimasertib | No dispute reported | 06/30/2026 | 1240091755 |
| Principal investigator 1 | PFIZER INC. | $114,601.20 | 10/21/2025 | Non-covered Recipient Entity Hoag Memorial Hospital | AN INTERVENTIONAL OPENLABEL RANDOMIZED MULTICENTER PHASE 3 STUDY OF PF07220060 PLUS LETROZOLE COMPARED TO CDK46 INHIBITOR PLUS LETROZOLE IN PARTICIPANTS OVER 18 YEARS OF AGE WITH HORMONE RECEPTOR HRPOSITIVE HER2NEGATIVE ADVANCEDMETASTATIC BREAST CANCER WHO HAVE NOT RECEIVED ANY PRIOR SYSTEMIC ANTICANCER TREATMENT FOR ADVANCEDMETASTATIC DISEASE FOURLIGHT3 | No dispute reported | 06/30/2026 | 1228716349 |
| Principal investigator 1 | PFIZER INC. | $15.00 | 10/21/2025 | Non-covered Recipient Entity Hoag Memorial Hospital | AN INTERVENTIONAL OPENLABEL RANDOMIZED MULTICENTER PHASE 3 STUDY OF PF07220060 PLUS LETROZOLE COMPARED TO CDK46 INHIBITOR PLUS LETROZOLE IN PARTICIPANTS OVER 18 YEARS OF AGE WITH HORMONE RECEPTOR HRPOSITIVE HER2NEGATIVE ADVANCEDMETASTATIC BREAST CANCER WHO HAVE NOT RECEIVED ANY PRIOR SYSTEMIC ANTICANCER TREATMENT FOR ADVANCEDMETASTATIC DISEASE FOURLIGHT3 | No dispute reported | 06/30/2026 | 1228716415 |
| Principal investigator 1 | JAZZ PHARMACEUTICALS INC. | $665.00 | 09/30/2025 | Non-covered Recipient Entity Hoag Memorial Hospital Presbyterian | I-SPY Trial (Investigation of Serial Studies to Predict Your Therapeutic Response With Imaging And moLecular Analysis 2) | No dispute reported | 06/30/2026 | 1233739997 |
| Principal investigator 1 | PFIZER INC. | $2,396.25 | 09/24/2025 | Non-covered Recipient Entity Hoag Memorial Hospital Presbyterian | AN INTERVENTIONAL SAFETY AND EFFICACY PHASE 1B2 OPENLABEL STUDY TO INVESTIGATE TOLERABILITY PK AND ANTITUMOR ACTIVITY OF VEPDEGESTRANT ARV471PF07850327 AN ORAL PROTEOLYSIS TARGETING CHIMERA IN COMBINATION WITH PF07220060 IN PARTICIPANTS AGED 18 YEARS AND OLDER WITH ERHER2 ADVANCED OR METASTATIC BREAST CANCER | No dispute reported | 06/30/2026 | 1228761111 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $943.00 | 09/23/2025 | Non-covered Recipient Entity HOAG MEMORIAL HOSPITAL PRESBYTERIAN | A Phase 2 and Phase 3 Peri-operative Trial of Fianlimab and Cemiplimab Compared With Anti-PD1 Alone in Patients With Resectable Stage III and IV Melanoma | No dispute reported | 06/30/2026 | 1184241682 |
| Principal investigator 1 | PFIZER INC. | $37,642.35 | 08/23/2025 | Non-covered Recipient Entity Hoag Memorial Hospital Presbyterian | AN INTERVENTIONAL SAFETY AND EFFICACY PHASE 1B2 OPENLABEL STUDY TO INVESTIGATE TOLERABILITY PK AND ANTITUMOR ACTIVITY OF VEPDEGESTRANT ARV471PF07850327 AN ORAL PROTEOLYSIS TARGETING CHIMERA IN COMBINATION WITH PF07220060 IN PARTICIPANTS AGED 18 YEARS AND OLDER WITH ERHER2 ADVANCED OR METASTATIC BREAST CANCER | No dispute reported | 06/30/2026 | 1228765943 |
| Principal investigator 1 | PFIZER INC. | $2,250.00 | 08/05/2025 | Non-covered Recipient Entity Hoag Memorial Hospital Presbyterian | AN INTERVENTIONAL SAFETY AND EFFICACY PHASE 1B2 OPENLABEL STUDY TO INVESTIGATE TOLERABILITY PK AND ANTITUMOR ACTIVITY OF VEPDEGESTRANT ARV471PF07850327 AN ORAL PROTEOLYSIS TARGETING CHIMERA IN COMBINATION WITH PF07220060 IN PARTICIPANTS AGED 18 YEARS AND OLDER WITH ERHER2 ADVANCED OR METASTATIC BREAST CANCER | No dispute reported | 06/30/2026 | 1228785204 |
| Principal investigator 1 | PFIZER INC. | $5,142.15 | 07/26/2025 | Non-covered Recipient Entity Hoag Memorial Hospital Presbyterian | AN INTERVENTIONAL SAFETY AND EFFICACY PHASE 1B2 OPENLABEL STUDY TO INVESTIGATE TOLERABILITY PK AND ANTITUMOR ACTIVITY OF VEPDEGESTRANT ARV471PF07850327 AN ORAL PROTEOLYSIS TARGETING CHIMERA IN COMBINATION WITH PF07220060 IN PARTICIPANTS AGED 18 YEARS AND OLDER WITH ERHER2 ADVANCED OR METASTATIC BREAST CANCER | No dispute reported | 06/30/2026 | 1228784107 |
| Principal investigator 1 | PFIZER INC. | $750.00 | 07/01/2025 | Non-covered Recipient Entity Hoag Memorial Hospital Presbyterian | AN INTERVENTIONAL SAFETY AND EFFICACY PHASE 1B2 OPENLABEL STUDY TO INVESTIGATE TOLERABILITY PK AND ANTITUMOR ACTIVITY OF VEPDEGESTRANT ARV471PF07850327 AN ORAL PROTEOLYSIS TARGETING CHIMERA IN COMBINATION WITH PF07220060 IN PARTICIPANTS AGED 18 YEARS AND OLDER WITH ERHER2 ADVANCED OR METASTATIC BREAST CANCER | No dispute reported | 06/30/2026 | 1228764006 |
| Principal investigator 1 | PFIZER INC. | $16,301.40 | 06/26/2025 | Non-covered Recipient Entity Hoag Memorial Hospital Presbyterian | AN INTERVENTIONAL OPENLABEL RANDOMIZED MULTICENTER PHASE 3 STUDY OF PF07220060 PLUS FULVESTRANT COMPARED TO INVESTIGATORS CHOICE OF THERAPY IN PARTICIPANTS OVER 18 YEARS OF AGE WITH HORMONE RECEPTORPOSITIVE HER2NEGATIVE ADVANCEDMETASTATIC BREAST CANCER WHOSE DISEASE PROGRESSED AFTER PRIOR CDK 46 INHIBITOR BASED THERAPY | No dispute reported | 06/30/2026 | 1228724450 |
| Principal investigator 1 | Day One Biopharmaceuticals | $1,000.00 | 06/05/2025 | Non-covered Recipient Entity HOAG MEMORIAL HOSPITAL PRESBYTERIAN | A Phase 1b/2, Open Label Study of DAY101 Monotherapy or Combination with Other Therapies for Patients with Recurrent, Progressive, or Refractory Solid Tumors Harboring MAPK Pathway Aberrations | No dispute reported | 06/30/2026 | 1240091175 |
| Principal investigator 1 | Day One Biopharmaceuticals | $1,000.00 | 06/05/2025 | Non-covered Recipient Entity HOAG MEMORIAL HOSPITAL PRESBYTERIAN | A Phase 1b/2, Open Label Study of DAY101 Monotherapy or Combination with Other Therapies for Patients with Recurrent, Progressive, or Refractory Solid Tumors Harboring MAPK Pathway Aberrations | No dispute reported | 06/30/2026 | 1240091177 |
| Principal investigator 1 | Day One Biopharmaceuticals | $1,000.00 | 06/05/2025 | Non-covered Recipient Entity HOAG MEMORIAL HOSPITAL PRESBYTERIAN | A Phase 1b/2, Open Label Study of DAY101 Monotherapy or Combination with Other Therapies for Patients with Recurrent, Progressive, or Refractory Solid Tumors Harboring MAPK Pathway Aberrations | No dispute reported | 06/30/2026 | 1240091179 |
| Principal investigator 1 | Day One Biopharmaceuticals | $438.61 | 05/15/2025 | Non-covered Recipient Entity HOAG MEMORIAL HOSPITAL PRESBYTERIAN | A Phase 1b/2, Open Label Study of DAY101 Monotherapy or Combination with Other Therapies for Patients with Recurrent, Progressive, or Refractory Solid Tumors Harboring MAPK Pathway Aberrations | No dispute reported | 06/30/2026 | 1240091091 |
| Principal investigator 1 | Day One Biopharmaceuticals | $48.74 | 05/15/2025 | Non-covered Recipient Entity HOAG MEMORIAL HOSPITAL PRESBYTERIAN | A Phase 1b/2, Open Label Study of DAY101 Monotherapy or Combination with Other Therapies for Patients with Recurrent, Progressive, or Refractory Solid Tumors Harboring MAPK Pathway Aberrations | No dispute reported | 06/30/2026 | 1240091093 |
| Principal investigator 1 | Day One Biopharmaceuticals | $48.74 | 05/15/2025 | Non-covered Recipient Entity HOAG MEMORIAL HOSPITAL PRESBYTERIAN | A Phase 1b/2, Open Label Study of DAY101 Monotherapy or Combination with Other Therapies for Patients with Recurrent, Progressive, or Refractory Solid Tumors Harboring MAPK Pathway Aberrations | No dispute reported | 06/30/2026 | 1240091095 |
| Principal investigator 1 | Day One Biopharmaceuticals | $438.61 | 05/15/2025 | Non-covered Recipient Entity HOAG MEMORIAL HOSPITAL PRESBYTERIAN | A Phase 1b/2, Open Label Study of DAY101 Monotherapy or Combination with Other Therapies for Patients with Recurrent, Progressive, or Refractory Solid Tumors Harboring MAPK Pathway Aberrations | No dispute reported | 06/30/2026 | 1240091097 |
| Principal investigator 1 | Day One Biopharmaceuticals | $98.14 | 05/15/2025 | Non-covered Recipient Entity HOAG MEMORIAL HOSPITAL PRESBYTERIAN | A Phase 1b/2, Open Label Study of DAY101 Monotherapy or Combination with Other Therapies for Patients with Recurrent, Progressive, or Refractory Solid Tumors Harboring MAPK Pathway Aberrations | No dispute reported | 06/30/2026 | 1240091099 |
| Principal investigator 1 | Day One Biopharmaceuticals | $438.61 | 05/15/2025 | Non-covered Recipient Entity HOAG MEMORIAL HOSPITAL PRESBYTERIAN | A Phase 1b/2, Open Label Study of DAY101 Monotherapy or Combination with Other Therapies for Patients with Recurrent, Progressive, or Refractory Solid Tumors Harboring MAPK Pathway Aberrations | No dispute reported | 06/30/2026 | 1240091101 |
| Principal investigator 1 | Day One Biopharmaceuticals | $438.61 | 05/15/2025 | Non-covered Recipient Entity HOAG MEMORIAL HOSPITAL PRESBYTERIAN | A Phase 1b/2, Open Label Study of DAY101 Monotherapy or Combination with Other Therapies for Patients with Recurrent, Progressive, or Refractory Solid Tumors Harboring MAPK Pathway Aberrations | No dispute reported | 06/30/2026 | 1240091103 |
| Principal investigator 1 | Day One Biopharmaceuticals | $438.61 | 05/15/2025 | Non-covered Recipient Entity HOAG MEMORIAL HOSPITAL PRESBYTERIAN | A Phase 1b/2, Open Label Study of DAY101 Monotherapy or Combination with Other Therapies for Patients with Recurrent, Progressive, or Refractory Solid Tumors Harboring MAPK Pathway Aberrations | No dispute reported | 06/30/2026 | 1240091105 |
| Principal investigator 1 | Day One Biopharmaceuticals | $438.61 | 05/15/2025 | Non-covered Recipient Entity HOAG MEMORIAL HOSPITAL PRESBYTERIAN | A Phase 1b/2, Open Label Study of DAY101 Monotherapy or Combination with Other Therapies for Patients with Recurrent, Progressive, or Refractory Solid Tumors Harboring MAPK Pathway Aberrations | No dispute reported | 06/30/2026 | 1240091107 |
| Principal investigator 1 | Day One Biopharmaceuticals | $48.74 | 05/15/2025 | Non-covered Recipient Entity HOAG MEMORIAL HOSPITAL PRESBYTERIAN | A Phase 1b/2, Open Label Study of DAY101 Monotherapy or Combination with Other Therapies for Patients with Recurrent, Progressive, or Refractory Solid Tumors Harboring MAPK Pathway Aberrations | No dispute reported | 06/30/2026 | 1240091109 |
| Principal investigator 1 | Day One Biopharmaceuticals | $48.74 | 05/15/2025 | Non-covered Recipient Entity HOAG MEMORIAL HOSPITAL PRESBYTERIAN | A Phase 1b/2, Open Label Study of DAY101 Monotherapy or Combination with Other Therapies for Patients with Recurrent, Progressive, or Refractory Solid Tumors Harboring MAPK Pathway Aberrations | No dispute reported | 06/30/2026 | 1240091111 |
| Principal investigator 1 | Day One Biopharmaceuticals | $48.74 | 05/15/2025 | Non-covered Recipient Entity HOAG MEMORIAL HOSPITAL PRESBYTERIAN | A Phase 1b/2, Open Label Study of DAY101 Monotherapy or Combination with Other Therapies for Patients with Recurrent, Progressive, or Refractory Solid Tumors Harboring MAPK Pathway Aberrations | No dispute reported | 06/30/2026 | 1240091113 |
| Principal investigator 1 | Day One Biopharmaceuticals | $48.74 | 05/15/2025 | Non-covered Recipient Entity HOAG MEMORIAL HOSPITAL PRESBYTERIAN | A Phase 1b/2, Open Label Study of DAY101 Monotherapy or Combination with Other Therapies for Patients with Recurrent, Progressive, or Refractory Solid Tumors Harboring MAPK Pathway Aberrations | No dispute reported | 06/30/2026 | 1240091115 |
| Principal investigator 1 | PFIZER INC. | $9,467.55 | 05/14/2025 | Non-covered Recipient Entity Hoag Memorial Hospital Presbyterian | AN INTERVENTIONAL OPENLABEL RANDOMIZED MULTICENTER PHASE 3 STUDY OF PF07220060 PLUS FULVESTRANT COMPARED TO INVESTIGATORS CHOICE OF THERAPY IN PARTICIPANTS OVER 18 YEARS OF AGE WITH HORMONE RECEPTORPOSITIVE HER2NEGATIVE ADVANCEDMETASTATIC BREAST CANCER WHOSE DISEASE PROGRESSED AFTER PRIOR CDK 46 INHIBITOR BASED THERAPY | No dispute reported | 06/30/2026 | 1228765391 |
| Principal investigator 1 | PFIZER INC. | $6,617.70 | 05/14/2025 | Non-covered Recipient Entity Hoag Memorial Hospital Presbyterian | AN INTERVENTIONAL SAFETY AND EFFICACY PHASE 1B2 OPENLABEL STUDY TO INVESTIGATE TOLERABILITY PK AND ANTITUMOR ACTIVITY OF VEPDEGESTRANT ARV471PF07850327 AN ORAL PROTEOLYSIS TARGETING CHIMERA IN COMBINATION WITH PF07220060 IN PARTICIPANTS AGED 18 YEARS AND OLDER WITH ERHER2 ADVANCED OR METASTATIC BREAST CANCER | No dispute reported | 06/30/2026 | 1228792986 |
| Principal investigator 1 | Day One Biopharmaceuticals | $504.23 | 05/08/2025 | Non-covered Recipient Entity HOAG MEMORIAL HOSPITAL PRESBYTERIAN | A Phase 1b/2, Open Label Study of DAY101 Monotherapy or Combination with Other Therapies for Patients with Recurrent, Progressive, or Refractory Solid Tumors Harboring MAPK Pathway Aberrations | No dispute reported | 06/30/2026 | 1240091057 |
| Principal investigator 1 | Day One Biopharmaceuticals | $56.02 | 05/08/2025 | Non-covered Recipient Entity HOAG MEMORIAL HOSPITAL PRESBYTERIAN | A Phase 1b/2, Open Label Study of DAY101 Monotherapy or Combination with Other Therapies for Patients with Recurrent, Progressive, or Refractory Solid Tumors Harboring MAPK Pathway Aberrations | No dispute reported | 06/30/2026 | 1240091059 |
| Principal investigator 1 | Day One Biopharmaceuticals | $560.25 | 05/08/2025 | Non-covered Recipient Entity HOAG MEMORIAL HOSPITAL PRESBYTERIAN | A Phase 1b/2, Open Label Study of DAY101 Monotherapy or Combination with Other Therapies for Patients with Recurrent, Progressive, or Refractory Solid Tumors Harboring MAPK Pathway Aberrations | No dispute reported | 06/30/2026 | 1240091061 |
| Principal investigator 1 | Day One Biopharmaceuticals | $504.23 | 05/08/2025 | Non-covered Recipient Entity HOAG MEMORIAL HOSPITAL PRESBYTERIAN | A Phase 1b/2, Open Label Study of DAY101 Monotherapy or Combination with Other Therapies for Patients with Recurrent, Progressive, or Refractory Solid Tumors Harboring MAPK Pathway Aberrations | No dispute reported | 06/30/2026 | 1240091063 |
| Principal investigator 1 | Day One Biopharmaceuticals | $56.02 | 05/08/2025 | Non-covered Recipient Entity HOAG MEMORIAL HOSPITAL PRESBYTERIAN | A Phase 1b/2, Open Label Study of DAY101 Monotherapy or Combination with Other Therapies for Patients with Recurrent, Progressive, or Refractory Solid Tumors Harboring MAPK Pathway Aberrations | No dispute reported | 06/30/2026 | 1240091065 |
| Principal investigator 1 | PFIZER INC. | $3,250.00 | 05/06/2025 | Non-covered Recipient Entity Hoag Memorial Hospital Presbyterian | AN INTERVENTIONAL OPENLABEL RANDOMIZED MULTICENTER PHASE 3 STUDY OF PF07220060 PLUS LETROZOLE COMPARED TO CDK46 INHIBITOR PLUS LETROZOLE IN PARTICIPANTS OVER 18 YEARS OF AGE WITH HORMONE RECEPTOR HRPOSITIVE HER2NEGATIVE ADVANCEDMETASTATIC BREAST CANCER WHO HAVE NOT RECEIVED ANY PRIOR SYSTEMIC ANTICANCER TREATMENT FOR ADVANCEDMETASTATIC DISEASE FOURLIGHT3 | No dispute reported | 06/30/2026 | 1228771800 |
| Principal investigator 1 | PFIZER INC. | $8,511.40 | 05/06/2025 | Non-covered Recipient Entity Hoag Memorial Hospital Presbyterian | AN INTERVENTIONAL SAFETY AND EFFICACY PHASE 1B2 OPENLABEL STUDY TO INVESTIGATE TOLERABILITY PK AND ANTITUMOR ACTIVITY OF VEPDEGESTRANT ARV471PF07850327 AN ORAL PROTEOLYSIS TARGETING CHIMERA IN COMBINATION WITH PF07220060 IN PARTICIPANTS AGED 18 YEARS AND OLDER WITH ERHER2 ADVANCED OR METASTATIC BREAST CANCER | No dispute reported | 06/30/2026 | 1228773262 |
| Principal investigator 1 | Day One Biopharmaceuticals | $158.22 | 05/05/2025 | Non-covered Recipient Entity HOAG MEMORIAL HOSPITAL PRESBYTERIAN | A Phase 1b/2, Open Label Study of DAY101 Monotherapy or Combination with Other Therapies for Patients with Recurrent, Progressive, or Refractory Solid Tumors Harboring MAPK Pathway Aberrations | No dispute reported | 06/30/2026 | 1240090917 |
| Principal investigator 1 | Day One Biopharmaceuticals | $138.51 | 05/05/2025 | Non-covered Recipient Entity HOAG MEMORIAL HOSPITAL PRESBYTERIAN | A Phase 1b/2, Open Label Study of DAY101 Monotherapy or Combination with Other Therapies for Patients with Recurrent, Progressive, or Refractory Solid Tumors Harboring MAPK Pathway Aberrations | No dispute reported | 06/30/2026 | 1240090933 |
| Principal investigator 1 | Day One Biopharmaceuticals | $48.74 | 05/05/2025 | Non-covered Recipient Entity HOAG MEMORIAL HOSPITAL PRESBYTERIAN | A Phase 1b/2, Open Label Study of DAY101 Monotherapy or Combination with Other Therapies for Patients with Recurrent, Progressive, or Refractory Solid Tumors Harboring MAPK Pathway Aberrations | No dispute reported | 06/30/2026 | 1240090955 |
| Principal investigator 1 | Day One Biopharmaceuticals | $915.05 | 05/05/2025 | Non-covered Recipient Entity HOAG MEMORIAL HOSPITAL PRESBYTERIAN | A Phase 1b/2, Open Label Study of DAY101 Monotherapy or Combination with Other Therapies for Patients with Recurrent, Progressive, or Refractory Solid Tumors Harboring MAPK Pathway Aberrations | No dispute reported | 06/30/2026 | 1240090965 |
| Principal investigator 1 | Day One Biopharmaceuticals | $158.22 | 05/05/2025 | Non-covered Recipient Entity HOAG MEMORIAL HOSPITAL PRESBYTERIAN | A Phase 1b/2, Open Label Study of DAY101 Monotherapy or Combination with Other Therapies for Patients with Recurrent, Progressive, or Refractory Solid Tumors Harboring MAPK Pathway Aberrations | No dispute reported | 06/30/2026 | 1240090967 |
| Principal investigator 1 | Day One Biopharmaceuticals | $48.74 | 05/05/2025 | Non-covered Recipient Entity HOAG MEMORIAL HOSPITAL PRESBYTERIAN | A Phase 1b/2, Open Label Study of DAY101 Monotherapy or Combination with Other Therapies for Patients with Recurrent, Progressive, or Refractory Solid Tumors Harboring MAPK Pathway Aberrations | No dispute reported | 06/30/2026 | 1240090969 |
| Principal investigator 1 | Day One Biopharmaceuticals | $169.70 | 05/05/2025 | Non-covered Recipient Entity HOAG MEMORIAL HOSPITAL PRESBYTERIAN | A Phase 1b/2, Open Label Study of DAY101 Monotherapy or Combination with Other Therapies for Patients with Recurrent, Progressive, or Refractory Solid Tumors Harboring MAPK Pathway Aberrations | No dispute reported | 06/30/2026 | 1240090971 |
| Principal investigator 1 | Day One Biopharmaceuticals | $55.08 | 05/05/2025 | Non-covered Recipient Entity HOAG MEMORIAL HOSPITAL PRESBYTERIAN | A Phase 1b/2, Open Label Study of DAY101 Monotherapy or Combination with Other Therapies for Patients with Recurrent, Progressive, or Refractory Solid Tumors Harboring MAPK Pathway Aberrations | No dispute reported | 06/30/2026 | 1240090973 |
| Principal investigator 1 | Day One Biopharmaceuticals | $757.23 | 05/05/2025 | Non-covered Recipient Entity HOAG MEMORIAL HOSPITAL PRESBYTERIAN | A Phase 1b/2, Open Label Study of DAY101 Monotherapy or Combination with Other Therapies for Patients with Recurrent, Progressive, or Refractory Solid Tumors Harboring MAPK Pathway Aberrations | No dispute reported | 06/30/2026 | 1240090975 |
| Principal investigator 1 | Day One Biopharmaceuticals | $48.74 | 05/05/2025 | Non-covered Recipient Entity HOAG MEMORIAL HOSPITAL PRESBYTERIAN | A Phase 1b/2, Open Label Study of DAY101 Monotherapy or Combination with Other Therapies for Patients with Recurrent, Progressive, or Refractory Solid Tumors Harboring MAPK Pathway Aberrations | No dispute reported | 06/30/2026 | 1240090977 |
| Principal investigator 1 | Day One Biopharmaceuticals | $226.80 | 05/05/2025 | Non-covered Recipient Entity HOAG MEMORIAL HOSPITAL PRESBYTERIAN | A Phase 1b/2, Open Label Study of DAY101 Monotherapy or Combination with Other Therapies for Patients with Recurrent, Progressive, or Refractory Solid Tumors Harboring MAPK Pathway Aberrations | No dispute reported | 06/30/2026 | 1240090979 |
| Principal investigator 1 | Day One Biopharmaceuticals | $232.47 | 05/05/2025 | Non-covered Recipient Entity HOAG MEMORIAL HOSPITAL PRESBYTERIAN | A Phase 1b/2, Open Label Study of DAY101 Monotherapy or Combination with Other Therapies for Patients with Recurrent, Progressive, or Refractory Solid Tumors Harboring MAPK Pathway Aberrations | No dispute reported | 06/30/2026 | 1240090981 |
| Principal investigator 1 | Day One Biopharmaceuticals | $48.74 | 05/05/2025 | Non-covered Recipient Entity HOAG MEMORIAL HOSPITAL PRESBYTERIAN | A Phase 1b/2, Open Label Study of DAY101 Monotherapy or Combination with Other Therapies for Patients with Recurrent, Progressive, or Refractory Solid Tumors Harboring MAPK Pathway Aberrations | No dispute reported | 06/30/2026 | 1240090983 |
| Principal investigator 1 | Day One Biopharmaceuticals | $84.78 | 05/05/2025 | Non-covered Recipient Entity HOAG MEMORIAL HOSPITAL PRESBYTERIAN | A Phase 1b/2, Open Label Study of DAY101 Monotherapy or Combination with Other Therapies for Patients with Recurrent, Progressive, or Refractory Solid Tumors Harboring MAPK Pathway Aberrations | No dispute reported | 06/30/2026 | 1240090985 |
| Principal investigator 1 | Day One Biopharmaceuticals | $56.02 | 05/05/2025 | Non-covered Recipient Entity HOAG MEMORIAL HOSPITAL PRESBYTERIAN | A Phase 1b/2, Open Label Study of DAY101 Monotherapy or Combination with Other Therapies for Patients with Recurrent, Progressive, or Refractory Solid Tumors Harboring MAPK Pathway Aberrations | No dispute reported | 06/30/2026 | 1240090987 |
| Principal investigator 1 | Day One Biopharmaceuticals | $48.74 | 05/05/2025 | Non-covered Recipient Entity HOAG MEMORIAL HOSPITAL PRESBYTERIAN | A Phase 1b/2, Open Label Study of DAY101 Monotherapy or Combination with Other Therapies for Patients with Recurrent, Progressive, or Refractory Solid Tumors Harboring MAPK Pathway Aberrations | No dispute reported | 06/30/2026 | 1240090989 |
| Principal investigator 1 | Day One Biopharmaceuticals | $158.22 | 05/05/2025 | Non-covered Recipient Entity HOAG MEMORIAL HOSPITAL PRESBYTERIAN | A Phase 1b/2, Open Label Study of DAY101 Monotherapy or Combination with Other Therapies for Patients with Recurrent, Progressive, or Refractory Solid Tumors Harboring MAPK Pathway Aberrations | No dispute reported | 06/30/2026 | 1240090991 |
| Principal investigator 1 | Day One Biopharmaceuticals | $56.02 | 05/05/2025 | Non-covered Recipient Entity HOAG MEMORIAL HOSPITAL PRESBYTERIAN | A Phase 1b/2, Open Label Study of DAY101 Monotherapy or Combination with Other Therapies for Patients with Recurrent, Progressive, or Refractory Solid Tumors Harboring MAPK Pathway Aberrations | No dispute reported | 06/30/2026 | 1240090993 |
| Principal investigator 1 | Day One Biopharmaceuticals | $48.74 | 05/05/2025 | Non-covered Recipient Entity HOAG MEMORIAL HOSPITAL PRESBYTERIAN | A Phase 1b/2, Open Label Study of DAY101 Monotherapy or Combination with Other Therapies for Patients with Recurrent, Progressive, or Refractory Solid Tumors Harboring MAPK Pathway Aberrations | No dispute reported | 06/30/2026 | 1240090995 |
| Principal investigator 1 | Day One Biopharmaceuticals | $163.89 | 05/05/2025 | Non-covered Recipient Entity HOAG MEMORIAL HOSPITAL PRESBYTERIAN | A Phase 1b/2, Open Label Study of DAY101 Monotherapy or Combination with Other Therapies for Patients with Recurrent, Progressive, or Refractory Solid Tumors Harboring MAPK Pathway Aberrations | No dispute reported | 06/30/2026 | 1240090997 |
| Principal investigator 1 | Day One Biopharmaceuticals | $203.44 | 05/05/2025 | Non-covered Recipient Entity HOAG MEMORIAL HOSPITAL PRESBYTERIAN | A Phase 1b/2, Open Label Study of DAY101 Monotherapy or Combination with Other Therapies for Patients with Recurrent, Progressive, or Refractory Solid Tumors Harboring MAPK Pathway Aberrations | No dispute reported | 06/30/2026 | 1240090999 |
| Principal investigator 1 | Day One Biopharmaceuticals | $158.22 | 05/05/2025 | Non-covered Recipient Entity HOAG MEMORIAL HOSPITAL PRESBYTERIAN | A Phase 1b/2, Open Label Study of DAY101 Monotherapy or Combination with Other Therapies for Patients with Recurrent, Progressive, or Refractory Solid Tumors Harboring MAPK Pathway Aberrations | No dispute reported | 06/30/2026 | 1240091001 |
| Principal investigator 1 | Day One Biopharmaceuticals | $48.74 | 05/05/2025 | Non-covered Recipient Entity HOAG MEMORIAL HOSPITAL PRESBYTERIAN | A Phase 1b/2, Open Label Study of DAY101 Monotherapy or Combination with Other Therapies for Patients with Recurrent, Progressive, or Refractory Solid Tumors Harboring MAPK Pathway Aberrations | No dispute reported | 06/30/2026 | 1240091003 |
| Principal investigator 1 | Day One Biopharmaceuticals | $163.89 | 05/05/2025 | Non-covered Recipient Entity HOAG MEMORIAL HOSPITAL PRESBYTERIAN | A Phase 1b/2, Open Label Study of DAY101 Monotherapy or Combination with Other Therapies for Patients with Recurrent, Progressive, or Refractory Solid Tumors Harboring MAPK Pathway Aberrations | No dispute reported | 06/30/2026 | 1240091005 |
| Principal investigator 1 | Day One Biopharmaceuticals | $48.74 | 05/05/2025 | Non-covered Recipient Entity HOAG MEMORIAL HOSPITAL PRESBYTERIAN | A Phase 1b/2, Open Label Study of DAY101 Monotherapy or Combination with Other Therapies for Patients with Recurrent, Progressive, or Refractory Solid Tumors Harboring MAPK Pathway Aberrations | No dispute reported | 06/30/2026 | 1240091007 |
| Principal investigator 1 | Day One Biopharmaceuticals | $487.23 | 05/05/2025 | Non-covered Recipient Entity HOAG MEMORIAL HOSPITAL PRESBYTERIAN | A Phase 1b/2, Open Label Study of DAY101 Monotherapy or Combination with Other Therapies for Patients with Recurrent, Progressive, or Refractory Solid Tumors Harboring MAPK Pathway Aberrations | No dispute reported | 06/30/2026 | 1240091009 |
| Principal investigator 1 | Day One Biopharmaceuticals | $158.22 | 05/05/2025 | Non-covered Recipient Entity HOAG MEMORIAL HOSPITAL PRESBYTERIAN | A Phase 1b/2, Open Label Study of DAY101 Monotherapy or Combination with Other Therapies for Patients with Recurrent, Progressive, or Refractory Solid Tumors Harboring MAPK Pathway Aberrations | No dispute reported | 06/30/2026 | 1240091011 |
| Principal investigator 1 | Day One Biopharmaceuticals | $220.32 | 05/05/2025 | Non-covered Recipient Entity HOAG MEMORIAL HOSPITAL PRESBYTERIAN | A Phase 1b/2, Open Label Study of DAY101 Monotherapy or Combination with Other Therapies for Patients with Recurrent, Progressive, or Refractory Solid Tumors Harboring MAPK Pathway Aberrations | No dispute reported | 06/30/2026 | 1240091013 |
| Principal investigator 1 | Day One Biopharmaceuticals | $599.55 | 05/05/2025 | Non-covered Recipient Entity HOAG MEMORIAL HOSPITAL PRESBYTERIAN | A Phase 1b/2, Open Label Study of DAY101 Monotherapy or Combination with Other Therapies for Patients with Recurrent, Progressive, or Refractory Solid Tumors Harboring MAPK Pathway Aberrations | No dispute reported | 06/30/2026 | 1240091015 |
| Principal investigator 1 | Day One Biopharmaceuticals | $48.74 | 05/05/2025 | Non-covered Recipient Entity HOAG MEMORIAL HOSPITAL PRESBYTERIAN | A Phase 1b/2, Open Label Study of DAY101 Monotherapy or Combination with Other Therapies for Patients with Recurrent, Progressive, or Refractory Solid Tumors Harboring MAPK Pathway Aberrations | No dispute reported | 06/30/2026 | 1240091017 |
| Principal investigator 1 | Day One Biopharmaceuticals | $158.22 | 05/05/2025 | Non-covered Recipient Entity HOAG MEMORIAL HOSPITAL PRESBYTERIAN | A Phase 1b/2, Open Label Study of DAY101 Monotherapy or Combination with Other Therapies for Patients with Recurrent, Progressive, or Refractory Solid Tumors Harboring MAPK Pathway Aberrations | No dispute reported | 06/30/2026 | 1240091027 |
| Principal investigator 1 | Day One Biopharmaceuticals | $504.23 | 05/01/2025 | Non-covered Recipient Entity HOAG MEMORIAL HOSPITAL PRESBYTERIAN | A Phase 1b/2, Open Label Study of DAY101 Monotherapy or Combination with Other Therapies for Patients with Recurrent, Progressive, or Refractory Solid Tumors Harboring MAPK Pathway Aberrations | No dispute reported | 06/30/2026 | 1240090907 |
| Principal investigator 1 | PFIZER INC. | $650.00 | 05/01/2025 | Non-covered Recipient Entity Hoag Memorial Hospital Presbyterian | AN INTERVENTIONAL OPENLABEL RANDOMIZED MULTICENTER PHASE 3 STUDY OF PF07220060 PLUS FULVESTRANT COMPARED TO INVESTIGATORS CHOICE OF THERAPY IN PARTICIPANTS OVER 18 YEARS OF AGE WITH HORMONE RECEPTORPOSITIVE HER2NEGATIVE ADVANCEDMETASTATIC BREAST CANCER WHOSE DISEASE PROGRESSED AFTER PRIOR CDK 46 INHIBITOR BASED THERAPY | No dispute reported | 06/30/2026 | 1228765053 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $3,250.00 | 04/15/2025 | Non-covered Recipient Entity HOAG MEMORIAL HOSPITAL PRESBYTERIAN | A Phase 2 and Phase 3 Peri-operative Trial of Fianlimab and Cemiplimab Compared With Anti-PD1 Alone in Patients With Resectable Stage III and IV Melanoma | No dispute reported | 06/30/2026 | 1184183352 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $3,903.00 | 04/15/2025 | Non-covered Recipient Entity HOAG MEMORIAL HOSPITAL PRESBYTERIAN | A Phase 2 and Phase 3 Peri-operative Trial of Fianlimab and Cemiplimab Compared With Anti-PD1 Alone in Patients With Resectable Stage III and IV Melanoma | No dispute reported | 06/30/2026 | 1184183354 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $2,341.00 | 04/15/2025 | Non-covered Recipient Entity HOAG MEMORIAL HOSPITAL PRESBYTERIAN | A Phase 2 and Phase 3 Peri-operative Trial of Fianlimab and Cemiplimab Compared With Anti-PD1 Alone in Patients With Resectable Stage III and IV Melanoma | No dispute reported | 06/30/2026 | 1184183356 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $15,800.00 | 04/15/2025 | Non-covered Recipient Entity HOAG MEMORIAL HOSPITAL PRESBYTERIAN | A Phase 2 and Phase 3 Peri-operative Trial of Fianlimab and Cemiplimab Compared With Anti-PD1 Alone in Patients With Resectable Stage III and IV Melanoma | No dispute reported | 06/30/2026 | 1184183358 |
| Principal investigator 1 | PFIZER INC. | $5,698.35 | 04/08/2025 | Non-covered Recipient Entity Hoag Memorial Hospital Presbyterian | AN INTERVENTIONAL SAFETY AND EFFICACY PHASE 1B2 OPENLABEL STUDY TO INVESTIGATE TOLERABILITY PK AND ANTITUMOR ACTIVITY OF VEPDEGESTRANT ARV471PF07850327 AN ORAL PROTEOLYSIS TARGETING CHIMERA IN COMBINATION WITH PF07220060 IN PARTICIPANTS AGED 18 YEARS AND OLDER WITH ERHER2 ADVANCED OR METASTATIC BREAST CANCER | No dispute reported | 06/30/2026 | 1228779951 |
| Principal investigator 1 | JAZZ PHARMACEUTICALS INC. | $328.90 | 03/30/2025 | Non-covered Recipient Entity Hoag Memorial Hospital Presbyterian | I-SPY Trial (Investigation of Serial Studies to Predict Your Therapeutic Response With Imaging And moLecular Analysis 2) | No dispute reported | 06/30/2026 | 1233739995 |
| Principal investigator 1 | PFIZER INC. | $18,586.00 | 03/26/2025 | Non-covered Recipient Entity Hoag Memorial Hospital Presbyterian | AN INTERVENTIONAL OPENLABEL RANDOMIZED MULTICENTER PHASE 3 STUDY OF PF07220060 PLUS LETROZOLE COMPARED TO CDK46 INHIBITOR PLUS LETROZOLE IN PARTICIPANTS OVER 18 YEARS OF AGE WITH HORMONE RECEPTOR HRPOSITIVE HER2NEGATIVE ADVANCEDMETASTATIC BREAST CANCER WHO HAVE NOT RECEIVED ANY PRIOR SYSTEMIC ANTICANCER TREATMENT FOR ADVANCEDMETASTATIC DISEASE FOURLIGHT3 | No dispute reported | 06/30/2026 | 1228788323 |
| Principal investigator 1 | Day One Biopharmaceuticals | $504.23 | 03/19/2025 | Non-covered Recipient Entity HOAG MEMORIAL HOSPITAL PRESBYTERIAN | A Phase 1b/2, Open Label Study of DAY101 Monotherapy or Combination with Other Therapies for Patients with Recurrent, Progressive, or Refractory Solid Tumors Harboring MAPK Pathway Aberrations | No dispute reported | 06/30/2026 | 1240090771 |
| Principal investigator 1 | PFIZER INC. | $3,017.75 | 03/14/2025 | Non-covered Recipient Entity Hoag Memorial Hospital Presbyterian | AN INTERVENTIONAL OPENLABEL RANDOMIZED MULTICENTER PHASE 3 STUDY OF PF07220060 PLUS FULVESTRANT COMPARED TO INVESTIGATORS CHOICE OF THERAPY IN PARTICIPANTS OVER 18 YEARS OF AGE WITH HORMONE RECEPTORPOSITIVE HER2NEGATIVE ADVANCEDMETASTATIC BREAST CANCER WHOSE DISEASE PROGRESSED AFTER PRIOR CDK 46 INHIBITOR BASED THERAPY | No dispute reported | 06/30/2026 | 1228782970 |
| Principal investigator 1 | PFIZER INC. | $2,840.60 | 02/22/2025 | Non-covered Recipient Entity Hoag Memorial Hospital Presbyterian | AN INTERVENTIONAL OPENLABEL RANDOMIZED MULTICENTER PHASE 3 STUDY OF PF07220060 PLUS FULVESTRANT COMPARED TO INVESTIGATORS CHOICE OF THERAPY IN PARTICIPANTS OVER 18 YEARS OF AGE WITH HORMONE RECEPTORPOSITIVE HER2NEGATIVE ADVANCEDMETASTATIC BREAST CANCER WHOSE DISEASE PROGRESSED AFTER PRIOR CDK 46 INHIBITOR BASED THERAPY | No dispute reported | 06/30/2026 | 1228761885 |
| Principal investigator 1 | AstraZeneca Pharmaceuticals LP | $45,544.70 | 02/19/2025 | Non-covered Recipient Entity HOAG MEMORIAL HOSPITAL PRESBYTERIAN | A Phase 3 Open-label, Randomised Study of Datopotamab Deruxtecan?(DatoDXd) With or Without Durvalumab Versus Investigators Choice of Therapy in Patients With Stage I-III Triple-negative Breast Cancer Who Have Residual Invasive Disease in the Breast and/or Axillary Lymph Nodes at Surgical Resection Following Neoadjuvant Systemic Therapy | No dispute reported | 06/30/2026 | 1185553375 |
| Principal investigator 1 | PFIZER INC. | $3,390.00 | 02/14/2025 | Non-covered Recipient Entity Hoag Memorial Hospital Presbyterian | AN INTERVENTIONAL SAFETY AND EFFICACY PHASE 1B2 OPENLABEL STUDY TO INVESTIGATE TOLERABILITY PK AND ANTITUMOR ACTIVITY OF VEPDEGESTRANT ARV471PF07850327 AN ORAL PROTEOLYSIS TARGETING CHIMERA IN COMBINATION WITH PF07220060 IN PARTICIPANTS AGED 18 YEARS AND OLDER WITH ERHER2 ADVANCED OR METASTATIC BREAST CANCER | No dispute reported | 06/30/2026 | 1228742692 |
| Principal investigator 1 | Day One Biopharmaceuticals | $438.61 | 02/10/2025 | Non-covered Recipient Entity HOAG MEMORIAL HOSPITAL PRESBYTERIAN | A Phase 1b/2, Open Label Study of DAY101 Monotherapy or Combination with Other Therapies for Patients with Recurrent, Progressive, or Refractory Solid Tumors Harboring MAPK Pathway Aberrations | No dispute reported | 06/30/2026 | 1240090647 |
| Principal investigator 1 | Day One Biopharmaceuticals | $438.61 | 02/10/2025 | Non-covered Recipient Entity HOAG MEMORIAL HOSPITAL PRESBYTERIAN | A Phase 1b/2, Open Label Study of DAY101 Monotherapy or Combination with Other Therapies for Patients with Recurrent, Progressive, or Refractory Solid Tumors Harboring MAPK Pathway Aberrations | No dispute reported | 06/30/2026 | 1240090649 |
| Principal investigator 1 | Day One Biopharmaceuticals | $438.61 | 02/10/2025 | Non-covered Recipient Entity HOAG MEMORIAL HOSPITAL PRESBYTERIAN | A Phase 1b/2, Open Label Study of DAY101 Monotherapy or Combination with Other Therapies for Patients with Recurrent, Progressive, or Refractory Solid Tumors Harboring MAPK Pathway Aberrations | No dispute reported | 06/30/2026 | 1240090651 |
| Principal investigator 1 | Day One Biopharmaceuticals | $438.61 | 02/10/2025 | Non-covered Recipient Entity HOAG MEMORIAL HOSPITAL PRESBYTERIAN | A Phase 1b/2, Open Label Study of DAY101 Monotherapy or Combination with Other Therapies for Patients with Recurrent, Progressive, or Refractory Solid Tumors Harboring MAPK Pathway Aberrations | No dispute reported | 06/30/2026 | 1240090653 |
| Principal investigator 1 | Day One Biopharmaceuticals | $438.61 | 02/10/2025 | Non-covered Recipient Entity HOAG MEMORIAL HOSPITAL PRESBYTERIAN | A Phase 1b/2, Open Label Study of DAY101 Monotherapy or Combination with Other Therapies for Patients with Recurrent, Progressive, or Refractory Solid Tumors Harboring MAPK Pathway Aberrations | No dispute reported | 06/30/2026 | 1240090655 |
| Principal investigator 1 | Day One Biopharmaceuticals | $495.72 | 02/10/2025 | Non-covered Recipient Entity HOAG MEMORIAL HOSPITAL PRESBYTERIAN | A Phase 1b/2, Open Label Study of DAY101 Monotherapy or Combination with Other Therapies for Patients with Recurrent, Progressive, or Refractory Solid Tumors Harboring MAPK Pathway Aberrations | No dispute reported | 06/30/2026 | 1240090657 |
| Principal investigator 1 | Day One Biopharmaceuticals | $438.61 | 02/10/2025 | Non-covered Recipient Entity HOAG MEMORIAL HOSPITAL PRESBYTERIAN | A Phase 1b/2, Open Label Study of DAY101 Monotherapy or Combination with Other Therapies for Patients with Recurrent, Progressive, or Refractory Solid Tumors Harboring MAPK Pathway Aberrations | No dispute reported | 06/30/2026 | 1240090659 |
| Principal investigator 1 | Day One Biopharmaceuticals | $438.61 | 02/10/2025 | Non-covered Recipient Entity HOAG MEMORIAL HOSPITAL PRESBYTERIAN | A Phase 1b/2, Open Label Study of DAY101 Monotherapy or Combination with Other Therapies for Patients with Recurrent, Progressive, or Refractory Solid Tumors Harboring MAPK Pathway Aberrations | No dispute reported | 06/30/2026 | 1240090661 |
| Principal investigator 1 | Day One Biopharmaceuticals | $438.61 | 02/10/2025 | Non-covered Recipient Entity HOAG MEMORIAL HOSPITAL PRESBYTERIAN | A Phase 1b/2, Open Label Study of DAY101 Monotherapy or Combination with Other Therapies for Patients with Recurrent, Progressive, or Refractory Solid Tumors Harboring MAPK Pathway Aberrations | No dispute reported | 06/30/2026 | 1240090663 |
| Principal investigator 1 | Day One Biopharmaceuticals | $438.61 | 02/10/2025 | Non-covered Recipient Entity HOAG MEMORIAL HOSPITAL PRESBYTERIAN | A Phase 1b/2, Open Label Study of DAY101 Monotherapy or Combination with Other Therapies for Patients with Recurrent, Progressive, or Refractory Solid Tumors Harboring MAPK Pathway Aberrations | No dispute reported | 06/30/2026 | 1240090665 |
| Principal investigator 1 | PFIZER INC. | $16,951.90 | 02/05/2025 | Non-covered Recipient Entity Hoag Memorial Hospital Presbyterian | AN INTERVENTIONAL OPENLABEL RANDOMIZED MULTICENTER PHASE 3 STUDY OF PF07220060 PLUS FULVESTRANT COMPARED TO INVESTIGATORS CHOICE OF THERAPY IN PARTICIPANTS OVER 18 YEARS OF AGE WITH HORMONE RECEPTORPOSITIVE HER2NEGATIVE ADVANCEDMETASTATIC BREAST CANCER WHOSE DISEASE PROGRESSED AFTER PRIOR CDK 46 INHIBITOR BASED THERAPY | No dispute reported | 06/30/2026 | 1228759786 |
| Principal investigator 1 | PFIZER INC. | $3,520.00 | 01/22/2025 | Non-covered Recipient Entity Hoag Memorial Hospital Presbyterian | AN INTERVENTIONAL OPENLABEL RANDOMIZED MULTICENTER PHASE 3 STUDY OF PF07220060 PLUS FULVESTRANT COMPARED TO INVESTIGATORS CHOICE OF THERAPY IN PARTICIPANTS OVER 18 YEARS OF AGE WITH HORMONE RECEPTORPOSITIVE HER2NEGATIVE ADVANCEDMETASTATIC BREAST CANCER WHOSE DISEASE PROGRESSED AFTER PRIOR CDK 46 INHIBITOR BASED THERAPY | No dispute reported | 06/30/2026 | 1228760259 |
| Principal investigator 1 | PFIZER INC. | $1,151.18 | 01/22/2025 | Non-covered Recipient Entity Hoag Memorial Hospital Presbyterian | AN INTERVENTIONAL OPENLABEL RANDOMIZED MULTICENTER PHASE 3 STUDY OF PF07220060 PLUS FULVESTRANT COMPARED TO INVESTIGATORS CHOICE OF THERAPY IN PARTICIPANTS OVER 18 YEARS OF AGE WITH HORMONE RECEPTORPOSITIVE HER2NEGATIVE ADVANCEDMETASTATIC BREAST CANCER WHOSE DISEASE PROGRESSED AFTER PRIOR CDK 46 INHIBITOR BASED THERAPY | No dispute reported | 06/30/2026 | 1228762424 |
| Principal investigator 1 | Janssen Research & Development, LLC | $10,000.00 | 01/21/2025 | Non-covered Recipient Entity Hoag Meml Hosp Presby | JNJ-90301900 (NBTXR3) Activated by Radiotherapy With or Without Cetuximab in LA-HNSCC | No dispute reported | 06/30/2026 | 1175174131 |
| Principal investigator 1 | Janssen Research & Development, LLC | $300.00 | 01/21/2025 | Non-covered Recipient Entity Hoag Meml Hosp Presby | JNJ-90301900 (NBTXR3) Activated by Radiotherapy With or Without Cetuximab in LA-HNSCC | No dispute reported | 06/30/2026 | 1175174194 |
| Principal investigator 1 | PFIZER INC. | $3,445.20 | 01/15/2025 | Non-covered Recipient Entity Hoag Memorial Hospital Presbyterian | AN INTERVENTIONAL OPENLABEL RANDOMIZED MULTICENTER PHASE 3 STUDY OF PF07220060 PLUS FULVESTRANT COMPARED TO INVESTIGATORS CHOICE OF THERAPY IN PARTICIPANTS OVER 18 YEARS OF AGE WITH HORMONE RECEPTORPOSITIVE HER2NEGATIVE ADVANCEDMETASTATIC BREAST CANCER WHOSE DISEASE PROGRESSED AFTER PRIOR CDK 46 INHIBITOR BASED THERAPY | No dispute reported | 06/30/2026 | 1228801883 |
| Principal investigator 1 | Day One Biopharmaceuticals | $225.00 | 01/02/2025 | Non-covered Recipient Entity HOAG MEMORIAL HOSPITAL PRESBYTERIAN | A Phase 1b/2, Open Label Study of DAY101 Monotherapy or Combination with Other Therapies for Patients with Recurrent, Progressive, or Refractory Solid Tumors Harboring MAPK Pathway Aberrations | No dispute reported | 06/30/2026 | 1240090411 |
| Principal investigator 1 | Day One Biopharmaceuticals | $225.00 | 01/02/2025 | Non-covered Recipient Entity HOAG MEMORIAL HOSPITAL PRESBYTERIAN | A Phase 1b/2, Open Label Study of DAY101 Monotherapy or Combination with Other Therapies for Patients with Recurrent, Progressive, or Refractory Solid Tumors Harboring MAPK Pathway Aberrations | No dispute reported | 06/30/2026 | 1240090413 |
| Principal investigator 1 | Day One Biopharmaceuticals | $2,157.00 | 01/02/2025 | Non-covered Recipient Entity HOAG MEMORIAL HOSPITAL PRESBYTERIAN | A Phase 1b/2, Open Label Study of DAY101 Monotherapy or Combination with Other Therapies for Patients with Recurrent, Progressive, or Refractory Solid Tumors Harboring MAPK Pathway Aberrations | No dispute reported | 06/30/2026 | 1240090415 |
| Principal investigator 1 | Day One Biopharmaceuticals | $225.00 | 01/02/2025 | Non-covered Recipient Entity HOAG MEMORIAL HOSPITAL PRESBYTERIAN | A Phase 1b/2, Open Label Study of DAY101 Monotherapy or Combination with Other Therapies for Patients with Recurrent, Progressive, or Refractory Solid Tumors Harboring MAPK Pathway Aberrations | No dispute reported | 06/30/2026 | 1240090417 |
| Principal investigator 1 | Day One Biopharmaceuticals | $2,157.00 | 01/02/2025 | Non-covered Recipient Entity HOAG MEMORIAL HOSPITAL PRESBYTERIAN | A Phase 1b/2, Open Label Study of DAY101 Monotherapy or Combination with Other Therapies for Patients with Recurrent, Progressive, or Refractory Solid Tumors Harboring MAPK Pathway Aberrations | No dispute reported | 06/30/2026 | 1240090419 |
| Principal investigator 1 | Day One Biopharmaceuticals | $2,157.00 | 01/02/2025 | Non-covered Recipient Entity HOAG MEMORIAL HOSPITAL PRESBYTERIAN | A Phase 1b/2, Open Label Study of DAY101 Monotherapy or Combination with Other Therapies for Patients with Recurrent, Progressive, or Refractory Solid Tumors Harboring MAPK Pathway Aberrations | No dispute reported | 06/30/2026 | 1240090421 |
| Principal investigator 1 | Day One Biopharmaceuticals | $217.00 | 01/02/2025 | Non-covered Recipient Entity HOAG MEMORIAL HOSPITAL PRESBYTERIAN | A Phase 1b/2, Open Label Study of DAY101 Monotherapy or Combination with Other Therapies for Patients with Recurrent, Progressive, or Refractory Solid Tumors Harboring MAPK Pathway Aberrations | No dispute reported | 06/30/2026 | 1240090423 |
| Principal investigator 1 | Day One Biopharmaceuticals | $217.00 | 01/02/2025 | Non-covered Recipient Entity HOAG MEMORIAL HOSPITAL PRESBYTERIAN | A Phase 1b/2, Open Label Study of DAY101 Monotherapy or Combination with Other Therapies for Patients with Recurrent, Progressive, or Refractory Solid Tumors Harboring MAPK Pathway Aberrations | No dispute reported | 06/30/2026 | 1240090437 |